Boehringer/Zealand Survodutide SYNCHRONIZE-1 hits 16.6% weight loss at 76 weeks; BI 3034701 triple agonist heads to Phase 2; Boston peptide summit opens; Nature peptide papers.
Read digest →Eli Lilly Q1 earnings April 30; C&EN dives into amylin's GLP-1 challenge; AJSM peptide primer for sports medicine; trevogrumab and apitegromab muscle-preservation race.
Read digest →Pre-earnings week ahead — Lilly Apr 30, Novo May 6; Survodutide Phase 3 H1 readout; patient-access analyses post-FDA peptide announcement; AI-designed peptide tooling.
Read digest →Hims expands Lilly partnership and gets JPMorgan Buy at $35; Crinetics SSTR2 NDC; Cerapedics P-15 peptide bone graft Vizient deal; ABC affiliates warn on unregulated peptides.
Read digest →Novo's PIONEER TEENS pediatric T2D oral semaglutide positive; Fractyl REMAIN-1 gut-reset prevents post-GLP-1 weight regain; Roche projects $9B obesity pipeline peak sales.
Read digest →Trump admin extends Medicare GLP-1 Bridge through 2027 with taxpayer dollars after BALANCE collapse; MBX previews three once-monthly peptide candidates; AACR wraps.
Read digest →Trump cancels Medicare GLP-1 pilot after CVS pullout, BPC-157/TB-500 formally exit FDA Cat 2, Avacta PDC shows 3x Enhertu selectivity, 12M lost Wegovy coverage.
Read digest →Amazon enters GLP-1 at $25/mo, Kailera's $625M IPO is biotech's biggest since 2023, Perspective's alpha-PRRT hits 43% ORR, and Sapience's peptide antagonist debuts.
Read digest →Tirzepatide beats semaglutide 21.6% vs 15.4% in SURMOUNT-5, Bicycle PDC hits 40% ORR, 69/74 medspas still sell compounded GLP-1s, AACR peptide vaccines advance.
Read digest →Circle Pharma's CID-078 macrocyclic peptide debuts at AACR clinical plenary; Bicycle's BT5528 HNSCC data; Fedora's FPI-2119 bactericidal profile at ESCMID; HMD-AMP AI finds 37M+ AMPs.
Read digest →GLP-1 pioneers DiMarchi/Tschöp propose non-GLP-1 obesity approach; ESCMID Global opens in Munich; Circle Pharma macrocyclic peptide data at AACR; Scientific American on the peptide craze.
Read digest →AACR 2026 opens with peptide cancer therapies in the spotlight; CAMPER AI-designed peptides kill MRSA persisters; Novo partners with OpenAI for drug discovery.
Read digest →Lilly's Foundayo ACHIEVE-4 data eases FDA concerns with 57% lower death risk; FDA peptide panelists expected to support broader access; non-GLP-1 peptide pipeline advances.
Read digest →FDA schedules July advisory panel on BPC-157 and 6+ peptides for compounding; Hims surges 12%; fewer than 1 in 4 GLP-1 patients stay on treatment after a year.
Read digest →FDA requests Foundayo post-market liver and heart data; Australia's TGA warns on unapproved peptides; PEPITEM matches infliximab for arthritis; AI discovers novel antimicrobials.
Read digest →Stanford discovers brain-targeted peptide rivaling Ozempic without side effects; CNN publishes comprehensive peptide guide; tirzepatide outperforms semaglutide at 12 months.
Read digest →ProPublica investigates risks of FDA peptide reclassification; semaglutide shows mixed results in depression trial; Noom acquires compounding pharmacy to enter peptide market.
Read digest →Apotex wins first generic semaglutide approval, retatrutide aces Phase III, and the Foundayo vs oral Wegovy rivalry intensifies.
Read digest →